Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

High RAB25 expression is associated with good clinical outcome in patients with locally advanced head and neck squamous cell carcinoma

  • Téllez-Gabriel, Marta
  • Arroyo Solera, Irene|||0000-0003-0425-1483
  • León i Vintró, Xavier|||0000-0001-6286-630X
  • Gallardo, Alberto|||0000-0002-2514-2027
  • López, Montserrat
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • López Pousa, Antonio|||0000-0003-1066-3951
  • Quer, Miquel|||0000-0003-2563-6729
  • Mangues, Ma Antonia|||0000-0002-1438-8515
  • Barnadas i Molins, Agustí|||0000-0002-0429-1349
  • Mangues, Ramon|||0000-0003-2661-9525
  • Pavón, Miguel A.
Currently there are no molecular markers able to predict clinical outcome in locally advanced head and neck squamous cell carcinoma (HNSCC). In a previous microarray study, RAB25 was identified as a potential prognostic marker. The aim of this study was to analyze the association between RAB25 expression and clinical outcome in patients with locally advanced HNSCC treated with standard therapy. In a retrospective immunohistochemical study (n = 97), we observed that RAB25-negative tumors had lower survival (log-rank, P = 0.01) than patients bearing positive tumors. In an independent prospective mRNA study (n = 117), low RAB25 mRNA expression was associated with poor prognosis. Using classification and regression tree analysis (CART) we established two groups of patients according to their RAB25 mRNA level and their risk of death. Low mRNA level was associated with poor local recurrence-free (log-rank, P = 0.005), progression-free (log-rank, P = 0.002) and cancer-specific (log-rank, P < 0.001) survival. Multivariate Cox model analysis showed that low expression of RAB25 was an independent poor prognostic factor for survival (hazard ratio: 3.84, 95% confidence interval: 1.93-7.62, P < 0.001). Patients whose tumors showed high RAB25 expression had a low probability of death after treatment. We also found lower RAB25 expression in tumors than in normal tissue (Mann-Whitney U, P < 0.001). Moreover, overexpression of RAB25 in the UM-SCC-74B HNSCC cell line increased cisplatin sensitivity, and reduced cell migration and invasion. Our findings support a tumor suppressor role for RAB25 in HNSCC and its potential use to identify locally advanced patients with a high probability of survival after genotoxic treatment. © 2013 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients

  • Pavón, Miguel Ángel|||0000-0003-3677-5329
  • Arroyo Solera, Irene|||0000-0003-0425-1483
  • Téllez Gabriel, Marta|||0000-0002-0895-2677
  • León i Vintró, Xavier|||0000-0001-6286-630X
  • Virós, David
  • López, Montserrat
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • López Pousa, Antonio|||0000-0003-1066-3951
  • Mangues, Ma Antonia|||0000-0002-1438-8515
  • Quer, Miquel|||0000-0003-2563-6729
  • Barnadas i Molins, Agustí|||0000-0002-0429-1349
  • Mangues, Ramon|||0000-0003-2661-9525
High SERPINE1 expression is a common event in head and neck squamous cell carcinoma (HNSCC); however, whether it plays a role in determining clinical outcome remains still unknown. We studied SERPINE1 as a prognostic marker in two HNSCC patient cohorts. In a retrospective study (n = 80), high expression of SERPINE1 was associated with poor progression-free (p = 0.022) and cancer-specific (p = 0.040) survival. In a prospective study (n = 190), high SERPINE1 expression was associated with poor local recurrence-free (p = 0.022), progression-free (p = 0.002) and cancer-specific (p = 0.006) survival. SERPINE1 expression was identified as an independent risk factor for progression-free survival in patients treated with chemo-radiotherapy or radiotherapy (p = 0.043). In both patient cohorts, high SERPINE1 expression increased the risk of metastasis spread (p = 0.045; p = 0.029). The association between SERPINE1 expression and survival was confirmed using the HNSCC cohort included in The Cancer Genome Atlas project (n = 507). Once again, patients showing high expression had a poorer survival (p < 0.001). SERPINE1 over-expression in HNSCC cells reduced cell proliferation and enhanced migration. It also protected cells from cisplatin-induced apoptosis, which was accompanied by PI3K/AKT pathway activation. Downregulation of SERPINE1 expression had the opposite effect. We propose SERPINE1 expression as a prognostic marker that could be used to stratify HNSCC patients according to their risk of recurrence.